Extensions — US Patent 12419895

As of April 26, 2026, the following is a detailed analysis of the patent term, application history, and related family for U.S. Patent 12,419,895.

Patent Term Adjustments (PTA) and Extensions (PTE)

Patent Term Adjustment (PTA): A detailed review of the prosecution history for U.S. Patent 12,419,895 and its parent applications indicates that there is no Patent Term Adjustment granted. The patent is subject to a terminal disclaimer, which disclaims any patent term extending beyond the statutory term of a parent patent. This often negates any PTA that might have otherwise accrued.
Patent Term Extension (PTE): There is no record of a Patent Term Extension having been filed or granted for U.S. Patent 12,419,895 under 35 U.S.C. § 156. Such extensions are typically sought for delays in regulatory review by the Food and Drug Administration (FDA) and must be filed within 60 days of product approval.

Application and Family History

U.S. Patent 12,419,895 has a complex prosecution history with numerous related applications, establishing a large patent family.

Application Number: 19/224,580
Filing Date: May 30, 2025

Continuation Applications

This patent is part of a long chain of continuation applications. A continuation is a patent application that allows an applicant to pursue additional claims to an invention disclosed in a prior, or "parent," application. The continuity chain for this patent is as follows:

U.S. Patent 12,419,895 (Application No. 19/224,580) is a continuation of:
- Application No. 18/988,636 (Now U.S. Patent 12,343,348)
  - Which is a continuation of Application No. 18/824,811 (Now U.S. Patent 12,178,823)
    - Which is a continuation of Application No. 18/421,914 (Now U.S. Patent 12,109,216)
      - Which is a continuation of Application No. 17/104,433 (Abandoned)
        
        Which is a continuation of Application No. 16/573,965 (Now U.S. Patent 10,874,676)
        
        Which is a continuation of Application No. 16/041,237 (Now U.S. Patent 10,456,408)
        
        Which is a continuation of Application No. 15/671,792 (Now U.S. Patent 10,058,557)

Divisional Application

The chain also includes a divisional application. A divisional application is carved out of a parent application and typically contains claims to a different invention that was also disclosed in the parent.

Application No. 15/671,792 (a continuation in the chain above) is a divisional of:
- Application No. 14/940,018 (Now U.S. Patent 9,757,384)

Priority Data

The entire family of patents and applications claims priority to several provisional applications, which establish the earliest effective filing date for the invention. The earliest priority date determines the 20-year term of the patent family.

Earliest Priority Date: The patent family claims priority to U.S. Provisional Application 62/080,150, filed on November 14, 2014.

Related Family Members

The prosecution history reveals a large family of related U.S. patents stemming from the same initial disclosure. Key granted patents in this family include:

U.S. Patent 9,757,384
U.S. Patent 10,058,557
U.S. Patent 10,456,408
U.S. Patent 10,874,676
U.S. Patent 12,109,216
U.S. Patent 12,178,823
U.S. Patent 12,343,348

Projected Expiration Date

The term of a U.S. patent is generally 20 years from the filing date of the earliest U.S. non-provisional application from which it claims priority.

Earliest Non-Provisional Filing Date: The earliest non-provisional application in this chain is Application No. 14/940,018, which was filed on November 12, 2015. However, the authoritative patent text for U.S. 12,419,895 claims priority from a provisional application filed on November 14, 2014. For calculating the 20-year term, the relevant date is the filing date of the first non-provisional application, which is November 12, 2015.
Calculation: November 12, 2015 + 20 years.
Adjustments: As there are no PTA or PTE grants, no days are added to the term.

Based on this information, the projected expiration date for U.S. Patent 12,419,895 is November 12, 2035.